The Author Replies  by Wish, Jay B.
Biosimilar recombinant human
erythropoietin induces the
production of neutralizing
antibodies
To the Editor: We have read with great interest the paper by
Praditpornsilpa et al.1 and the related comment by Wish2
about induction of neutralizing antibodies by biosimilar
epoetin products in Thailand. As far as we know, the only
Argentine-manufactured epoetin marketed in Thailand is
Hemax (Bio Sidus SA, Buenos Aires, Argentina), which is
probably the Argentine product mentioned in Pradit-
pornsilpa’s report, together with products of other origins.
The induction of such antibodies seems to be a class effect of
erythropoiesis stimulators and we agree that it is shared by
biosimilar and innovator epoetins. This concept emphasizes
the importance of a pharmacovigilance plan and risk minimi-
zation strategies for epoetin products. However, some statements
in both articles can be misleading, including the putative
existence of a pure red-cell aplasia (PRCA) epidemic induced
by biosimilar epoetins in Thailand and the assumption that
no pharmacovigilance is performed for such products.
A point estimation of antibodies and aplasia (as in the report
by Praditpornsilpa et al.1) does not mean/demonstrate the
existence of epidemic PRCA induced by biosimilars, as sug-
gested by Wish.2 Hemax was registered in Argentina in 1990,
before the biosimilarity concept arose in Europe, and its
formulation has remained unchanged. Pharmacovigilance
activities on Hemax include antibodies detection since 1998.
Hemax has been in the Thai market since 1997 and, upon
requirement of the local licensee, since February 2004 (after
the outbreak of PRCA associated to an innovator epoetin
product and related to formulation changes), we began to
receive sera for anti-epoetin testing from a few patients
treated with Hemax that reported loss of efﬁcacy. We suspect
that the increased rate of requirements for anti-epoetin antibodies
fromThailand reﬂects the increased interest on PRCA triggered
by the epidemics associated to Eprex, in a country in which
the rate of aplastic anemia is higher than in Western countries,3
involving probably human leukocyte antigen background.
The worldwide rate of PRCA associated to Hemax,
estimated in 2007 in 1.21 cases per 100,000 treatment-years,4
seems similar to reports with other epoetins, excluding the
already mentioned epidemics induced by Eprex.
A prospective study, including data from all epoetin
marketed in Thailand, as the one currently under way by the
Thai FDA (together with three Thai scientiﬁc societies),
should provide a more precise assessment of prevalence and
association between PRCA and epoetin products.
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The Author Replies: Ferro and Gonzalez1 describe as mis-
leading statements in the article by Praditpornsilpa et al.2 and
in the accompanying commentary by this author3 that there
was an epidemic of pure red cell aplasia (PRCA) in Thailand,
and that it was caused by the use of biosimilar erythropoiesis-
stimulating agents (ESAs). One could dispute that 23 patients
with PRCA who were receiving biosimilar ESAs in Thailand
constitutes an epidemic based on patient counts, but an
incidence rate of 1:2068 is certainly alarming when compared
with the virtual absence of ESA-associated PRCA in the
United States where biosimilar ESAs are not used. Whether
the incidence of PRCA associated with biosimilar ESA use is
signiﬁcantly higher than the background incidence of PRCA
in Thailand unassociated with ESA use was not addressed
by Praditpornsilpa et al.,2 but this question underscores the
importance of tailoring the post-marketing pharmacovigilance
program to the speciﬁc patient characteristics of each country
as the immunogenicity of biosimilars and other therapeutic
agents has a genetic predisposition. That said, a high back-
ground rate of idiopathic PRCA, an autoimmune disease, in
Thailand should be cause for more pharmacovigilance in that
country, not less. Irrespective of whether the current state of
pharmacovigilance for biosimilar ESAs is currently adequate
to assure the safety of patients receiving these agents, this
author agrees with Ferro and Gonzalez, Praditpornsilpa et al.,2
and drug regulatory agencies throughout the world that it can
be better, especially as increasing numbers of biosimilar agents
become available and their market share vs. the reference
agent increases because of patent expirations and efforts at
cost-containment.
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The Authors Reply: We have read the letter to the editor by
Hugo and Eliseo.1 Although all erythropoiesis-stimulating
agent (ESA) products have potential immunogenicity, we do
not think that induction of the recombinant erythropoietin
antibody seems to be a class effect of ESA. Combe et al.2 and
Singh3 have investigated biosimilar erythropoietins and showed
tremendously different characteristics from one product to
another, most likely resulting from the complexity of recombinant
protein manufacturing. Thus, the stringent regulations and
pharmacovigilance of each individual product is mandatory
to ensure patients’ safety.
All follow-up on recombinant erythropoietins in Thailand
has been licensed with limited nonclinical/clinical data and
without quality data, which makes it difﬁcult to deﬁne these
products as biosimilar by EMEA deﬁnition.4 The registration
of these products was licensed by generic chemical drug
paradigm, and pharmacovigilance was not required. The Thai
Food and Drug Administration (FDA) has now been revising
the regulation including the license revision. On reviewing the
data with the Thai FDA, we found that the pharmacovigilance
plan of follow-up on recombinant erythropoietins in Thailand
has never been submitted by any pharmaceutical industries.
Pharmacovigilance is a proactive, well-planned action
formally submitted to the regulator to monitor drug-related
problems that may not be evidenced during the pre-
marketing period. The Thai ESA registry has been initiated
by Thai FDA and scientiﬁc societies, not the pharmaceu-
tical industries, aiming to provide more precise risk of the
immunogenicity.
Although aplastic anemia has been reported with higher
incidence in Thailand compared with the West, this back-
ground has no link to the pathogenesis of anti-recombinant
erythropoietin-associated pure red cell aplasia. The induction
of neutralizing antibody of recombinant erythropoietins
causes maturation arrest of erythroblasts and consequently
pure red cell aplasia, whereas environmental toxin exposure
causes damage of hematologic stem cells, resulting in
pancytopenia and thus aplastic anemia.
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Hemodialysis vs. peritoneal
dialysis in chronic heart failure:
getting to the heart of the matter
To the Editor: REIN registry data published by Sens et al.1
imply a survival beneﬁt for hemodialysis (HD) in end-stage
renal disease patients with chronic heart failure (CHF)
condition when starting HD or peritoneal dialysis (PD).
However, concerns relate to the correct CHF characterization
in this study. Besides the nephrologist’s judgment and a
crude New York Heart Association (NYHA) classiﬁcation
(combined class NYHA III–IV), the degree of CHF remains
unclear. Speciﬁcally, echocardiographic parameters of systolic
or diastolic cardiac function were not provided. Second, CHF
diagnosis was not ascertained at least one more time after
dialysis onset. Thus, initial overhydration due to renal failure
mimicking CHF cannot be ruled out. Third, no differentiation
was made between valvular and non-valvular CHF. Finally,
no speciﬁc NYHA class differentiation, i.e., the presence of
NYHA class III or IV, was provided. When using the
combination of NYHA III–IV, more PD patients may belong
to NYHA IV and, vice versa, more HD patients may belong to
NYHA III, which may represent an additional confounding
issue. The prognosis for NYHA class-III or class-IV patients is
quite different.2 Thus, the combination of NYHA III–IV may
have obscured a survival beneﬁt for either dialysis modality.
Unfortunately, neither brain natriuretic peptide (BNP) nor
NT-proBNP, surrogates of CHF, was determined. BNP could
have provided additional information on cardiorenal syn-
drome when interpreted over time after onset of dialysis.3
Until proven otherwise, the main outcome, survival, may have
been confounded by more severe CHF in terms of more
NYHA class-IV patients in the PD group.
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